Relative Efficacy of Simeprevir (Smv) Versus Telaprevir (Tpv) In The Treatment of NaÏVe Genotype 1 Chronic Hepatitis C Patients, Based on Indirect Comparison Using Patient-Level Clinical Trial Data

To indirectly estimate the relative treatment effect of 12 weeks of treatment with SMV versus TPV in combination with response-guided background therapy of 24/48 weeks of Peginterferon/ribavirine (PR) in previously untreated patients with genotype 1 chronic hepatitis C virus infection, using patient-level data from the pivotal phase III-trials.

Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: J Diels, P Thilakarathne, S Van Sanden, U Sbarigia, A Mehnert Source Type: research